3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
7
Gastrointestinal Stromal Tumors
4
Hemangiosarcoma
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Melanoma
2
Lymphoma
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma Of Esophagus
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Liver Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Interventions
Doxorubicin
19
Ifosfamide
12
Radiotherapy
11
pembrolizumab
6
Nivolumab
6
Ipilimumab
6
pazopanib
4
Specimen Handling
4
Radiation
4
Gemcitabine
4
Docetaxel
4
CTLA-4 Antigen
4
Biopsy
4
Trabectedin
3
Sunitinib
3
Magnetic Resonance Spectroscopy
3
pegfilgrastim
2
liposomal doxorubicin
2
cabozantinib
2
brostallicin
2
X-Rays
2
Radiotherapy, Conformal
2
Radiation Dose Hypofractionation
2
Methotrexate
2
Imatinib Mesylate
2
Filgrastim
2
Etoposide
2
Diathermy
2
Cisplatin
2
Chemotherapy, Adjuvant
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
spartalizumab
×
Sarcoma
×
Clear all
NCT05961761
2023-07-27
PROPANE
Herlev and Gentofte Hospital
Phase 2
Recruiting
80 enrolled